Effects of anti-inflammatory treatment on fibroblast growth factor-21 in obesity and metabolic syndrome

AbstractFibroblast growth factor-21 (FGF21) is elevated in patients with the metabolic syndrome. Although the exact underlying mechanisms remain ill-defined, chronic low-grade inflammation with increased Interleukin-(IL)-1β expression may be responsible. The aim of this study was to investigate effects of two different anti-inflammatory treatments (IL-1 antagonism or high-dose corticosteroids) on FGF21 in patients with the metabolic syndrome. This is a secondary analysis of two interventional studies in patients with obesity and features of the metabolic syndrome. Trial A was an interventional trial (n = 73) investigating short-term effects of the IL-1 antagonist anakinra and of dexamethasone. Trial B was a randomized, placebo-controlled, double-blinded trial (n = 67) investigating longer-term effects of IL-1 antagonism. In total, 140 patients were included in both trials. Median age was 55 years (IQR 44–66), 26% were female and median BMI was 37 kg/m2 (IQR 34–39). Almost half of the patients were diabetic (45%) and had increased c-reactive protein levels of 3.4 mg/L. FGF21 levels correlated with fasting glucose levels, HOMA-index, C-peptide levels, HbA1c and BMI. Short-term treatment with anakinra led to a reduction of FGF21 levels by − 200 pg/mL (95%CI − 334 to − 66; p = 0.004). No effect was detectable after longer-term treatment (between-group difference: − 8.8 pg/mL (95%CI − 130.9 to 113.3; p = 0.89). Acute treatment with dexamethasone was associated with reductions of FGF21 by -175 pg/mL (95%CI − 236 to − 113; p < 0.001). Anti-inflammatory treatment with both, IL-1 antagonism and corticosteroids reduced FGF21 levels at short-term in individuals with the metabolic syndrome.Trial registration: ClinicalTrials.gov Identifiers NCT02672592 and NCT00757276.

Download Full-text

Fibroblast growth factor-21 levels in metabolic syndrome: Another instrument in a widening tool belt?

Atherosclerosis ◽

10.1016/j.atherosclerosis.2018.12.001 ◽

2019 ◽

Vol 281 ◽

pp. 143-144 ◽

Cited By ~ 1

Author(s):

Oluremi Ajala ◽

Samia Mora

Keyword(s):

Metabolic Syndrome ◽

Growth Factor ◽

Fibroblast Growth Factor ◽

Fibroblast Growth Factor 21 ◽

Fibroblast Growth

Download Full-text

Fibroblast Growth Factor 21 and Metabolic Dysfunction in Women with a Prior Glucose-Intolerant Pregnancy

American Journal of Perinatology ◽

10.1055/s-0040-1712966 ◽

2020 ◽

Author(s):

Celeste Durnwald ◽

Lisa Mele ◽

Mark B. Landon ◽

Michael W. Varner ◽

Brian M. Casey ◽

...

Keyword(s):

Metabolic Syndrome ◽

Growth Factor ◽

Fibroblast Growth Factor ◽

Fibroblast Growth Factor 21 ◽

Prior History ◽

Metabolic Dysfunction ◽

Fibroblast Growth ◽

Index Pregnancy ◽

History Of

Abstract Objective We sought to determine if there is an association between fibroblast growth factor 21 (FGF21) levels and a history of gestational diabetes mellitus (GDM) in women with and without metabolic dysfunction, defined as a diagnosis of metabolic syndrome or type 2 diabetes (T2DM), 5 to 10 years following participation in a multiple cohort GDM study. Study Design At 5 to 10 years after index pregnancy, women underwent a follow-up visit and were categorized as having no metabolic syndrome, metabolic syndrome, or T2DM. FGF21 levels were compared between women who did and did not have a history of GDM using multivariable linear regression. Results Among 1,889 women, 950 underwent follow-up and 796 had plasma samples analyzed (413 GDM and 383 non-GDM). Total 30.7% of women had been diagnosed with T2DM or metabolic syndrome. Overall, there was no difference in median FGF21 levels in pg/mL between the prior GDM and non-GDM groups (p = 0.12), and the lack of association was observed across all three metabolic categories at follow-up (p for interaction = 0.70). Conclusion There was no association between FGF21 levels and prior history of mild GDM in women with and without metabolic dysfunction 5 to 10 years after the index pregnancy (ClinicalTrials.gov number, NCT00069576, original trial).

Download Full-text

Relationship between fibroblast growth factor 21 and thyroid stimulating hormone in healthy subjects without components of metabolic syndrome

Family Medicine and Community Health ◽

10.15212/fmch.2014.0118 ◽

2014 ◽

Vol 2 (3) ◽

pp. 1-6

Author(s):

Tianxu Fu ◽

Shanshan Yuan ◽

Ying Gao ◽

Chenxue Qu ◽

Lan Chen ◽

...

Keyword(s):

Metabolic Syndrome ◽

Growth Factor ◽

Fibroblast Growth Factor ◽

Healthy Subjects ◽

Thyroid Stimulating Hormone ◽

Fibroblast Growth Factor 21 ◽

Fibroblast Growth ◽

Stimulating Hormone

Download Full-text

Evaluation of Total Adiponectin, Adipocyte Fatty Acid Binding Protein and Fibroblast Growth Factor 21 Levels in Individuals With Metabolic Syndrome

Physiological Research ◽

10.33549/physiolres.932602 ◽

2014 ◽

pp. 219-228 ◽

Cited By ~ 9

Author(s):

D. NOVOTNY ◽

H. VAVERKOVA ◽

D. KARASEK ◽

J. LUKES ◽

L. SLAVIK ◽

...

Keyword(s):

Metabolic Syndrome ◽

Fatty Acid ◽

Growth Factor ◽

Fibroblast Growth Factor ◽

Fatty Acid Binding Protein ◽

Binding Protein ◽

Fibroblast Growth Factor 21 ◽

Fibroblast Growth ◽

Fatty Acid Binding ◽

Acid Binding Protein

Although many studies have investigated the relationships of several adipokines to metabolic syndrome (MetS), the interrelationships of adiponectin (ADP), adipocyte fatty acid binding protein (A-FABP) and fibroblast growth factor 21 (FGF 21) have not been described in detail. We examined 209 asymptomatic dyslipidemic patients divided into MetS+ (n=73) and MetS- (n=136) groups. The aim of study was to evaluate the relationships between observed adipokines, to compare the levels of total ADP, A-FABP and FGF 21 in individuals with and without MetS, and to elucidate the relationships of individual adipokines to lipid parameters, markers of insulin resistance and endothelial hemostatic markers in these groups. In MetS+ group, we found the independent positive association ADP with A-FABP (beta=0.4888, p=0.0382), A-FABP with FGF 21 (beta=0.3811, p=0.0002) and von Willebrand factor (beta=0.4502, p=0.0013), and FGF 21 with A-FABP (beta=0.4422, p=0.0002). Our study has confirmed the well-established risk profile of subjects with MetS, although clinically asymptomatic. MetS+ patients had also lower levels of ADP and higher levels of A-FABP and FGF 21. Our study evaluated the interrelationships of ADP, A-FABP and FGF 21 in asymptomatic dyslipidemic subjects with diagnosis of MetS. Especially strong association between A-FABP and FGF 21 needs to be clarified in further studies.

Download Full-text